- 5 Redfors A. Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation. *Acta Med Scand* 1971;**190**:321-33.
- 6 McHaffie D, Smith D, O'Donnell T. Does digoxin control the heart rate on exercise in patients with atrial fibrillation? In: Oo TY, ed. *Proceedings of the sixteenth Singapore-Malaysia congress of medicine, Singapore, 1983*. Singapore: Academy of Medicine, Singapore, 1983:158-61.
- 7 Klein H, Pauzer H, De Signi E, David D, Kaplinsky E. The beneficial effects of verapamil in chronic atrial fibrillation. *Arch Intern Med* 1979;**139**:747-9.
- 8 Yahalom J, Klein H, Kaplinsky E. Beta adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. *Chest* 1977;**71**:592-6.
- 9 Sokolow M, McIlroy MB. *Clinical cardiology*. 3rd ed. Los Altos: Lange, 1981: 556-7, 642.
- 10 Duncan G, Johnson RH, Lambie DG, Whiteside EA. Evidence of vagal neuropathy in chronic alcoholics. *Lancet* 1980;ii:1053-7.
- 11 Smith TW, Butler VP, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. *N Engl J Med* 1969;**281**:1212-6.

- 12 Smith DA, O'Donnell TV. The time course during 36 weeks endurance training of changes in VO₂max and anaerobic threshold as determined with a new computerized method. *Clin Sci* 1984;**67**:229-36.
- 13 Bevington PR. *Data reduction and error analysis for the physical sciences*. New York: McGraw Hill, 1969:255-60.
- 14 Astrand P-O, Rodahl K. *Textbook of work physiology*. 2nd ed. New York: McGraw Hill, 1977:187-90, 321.
- 15 van der Walt WH, Wyndham CH. An equation for prediction of energy expenditure of walking and running. *J Appl Physiol* 1973;**34**:559-67.
- 16 Moe GK, Farah AE. Digitalis and allied cardiac glycosides. In: Goodman L, Gilman A, eds. *The pharmacological basis of therapeutics*. New York: Macmillan, 1965:674.
- 17 Rowell LB. Human cardiovascular adjustments to exercise and thermal stress. *Physiol Rev* 1974;**54**:75-159.

(Accepted 24 September 1984)

Thyroxine, methimazole, and thyroid microsomal autoantibody titres in hypothyroid Hashimoto's thyroiditis

ROLF JANSSON, ANDERS KARLSSON, PER ANDERS DAHLBERG

Abstract

Ten hypothyroid patients with Hashimoto's thyroiditis were treated with methimazole 30 mg in addition to thyroxine 0.15 mg daily. Another 10 hypothyroid patients with Hashimoto's thyroiditis were given thyroxine 0.15 mg alone. After 22 weeks of treatment significant decreases in thyroid microsomal autoantibody titres were observed in both groups ($p < 0.01$). There was no difference in the mean change in titre between the two groups. When the patients treated with methimazole were subsequently given thyroxine 0.15 mg alone for a further 22 weeks no additional change in titre was observed.

The data suggest that thyroxine, by normalising serum thyroid stimulating hormone concentrations, may reduce the autoantigenic properties of the thyrocytes with a subsequent decrease in autoantibody titres.

Introduction

Treatment of Graves' thyrotoxicosis with thionamide drugs, such as methimazole, carbimazole, and propylthiouracil, is accompanied by a decrease in thyroid autoantibody titres.¹⁻⁵ These thyrostatic drugs, which are known to be accumulated in the thyroid,⁶ have been suggested to have an immunosuppressive effect on antibody producing lymphocytes or antigen presenting monocytes located in the thyroid.^{4, 7, 8} We compared the effects of methimazole combined with thyroxine and of thyroxine alone on the titres of thyroid microsomal autoantibodies in hypothyroid patients with Hashimoto's thyroiditis. Both regimens were found to lower the antibody titres to the same extent.

Subjects and methods

Twenty patients (19 women and one man), who were referred to our outpatient thyroid clinic because of hypothyroidism, participated in the study after giving their informed consent. All patients had autoimmune goitrous thyroiditis (Hashimoto's thyroiditis), the diagnosis being based on the presence of serum thyroid microsomal autoantibodies and lymphocytic thyroiditis in fine needle aspiration biopsy specimens from the thyroid. The table shows the characteristics of the 20 patients.

The study, which was approved by the ethical committee of Uppsala University, was designed as follows (figure). Ten of the patients were treated with thyroxine and methimazole for 28 weeks (group 1). Thyroxine (Levaxin; Nyegaard, Oslo, Norway) was increased gradually by 0.05 mg every second week to a final dose of 0.15 mg. Methimazole (Thacapzol; KabiVitrum, Stockholm, Sweden) was similarly increased by 10 mg every second week to a final dose of 30 mg daily. Both drugs were given by mouth three times a day. This treatment was given for another 20 weeks and then gradually withdrawn over four weeks by 0.05 mg and 10 mg, respectively, every second week. After four weeks without treatment thyroxine alone was started again as in the initial treatment period. Another 10 patients (group 2) were given the same thyroxine treatment as group 1, but methimazole was omitted.

Blood samples were drawn zero, six, 14, 22, 30, 38, 46, and 54 weeks after the start of treatment in group 1, and thyroid function was consecutively analysed by routine radioimmunoassay methods. Similarly, blood samples were drawn zero, six, 14, 22, and 30 weeks after the start of treatment in group 2. One aliquot of serum from each sampling occasion was kept frozen at -20°C . After completion of the study all aliquots were analysed in a single assay run for the titre of thyroid microsomal autoantibodies by a commercial haemagglutination method (Thymune-M; Wellcome, Beckenham, UK). Fine needle aspiration biopsies were performed and evaluated at the department of cytology in this hospital. Serum methimazole was determined with a gas chromatographic mass spectrometric method.⁹

Student's t test for paired and unpaired data was used for statistical evaluation. The thyroid microsomal autoantibody titres were logarithmically transformed before calculations: 1:50 = 1, 1:100 = 2, 1:200 = 3, ... 1:409600 = 14.

Results

The figure shows the individual and mean thyroid microsomal autoantibody titres before and after 22 weeks of treatment in the two groups of patients. The mean thyroid microsomal autoantibody titre decreased significantly in both ($p < 0.01$ by paired t test in both groups). In both groups the microsomal autoantibody titres decreased in eight patients and remained unchanged in two. The mean decrease was similar in the two groups (NS by t test for groups).

In three patients treatment could not, for ethical reasons, be with-

Department of Internal Medicine, University Hospital, S-751 85 Uppsala, Sweden

ROLF JANSSON, MD, registrar

ANDERS KARLSSON, MD, associate professor

PER ANDERS DAHLBERG, MD, associate professor

Correspondence to: Dr R Jansson.

drawn as planned after 28 weeks. In the remaining patients the mean thyroid microsomal autoantibody titre did not change in either group in the period after treatment. When thyroxine alone was subsequently given for another 22 weeks (figure) to patients in group 1 no significant change in mean thyroid microsomal autoantibody titre was observed.

Individual (—) and mean (—) serum thyroid microsomal antibody titres in group 1 (treated with thyroxine and methimazole combined followed by thyroxine alone) and group 2 (treated with thyroxine alone). (Significance by paired *t* test: ***p* < 0.01.)

All patients had a raised serum thyroid stimulating hormone concentration before treatment (table), and this returned to normal during treatment in all cases. The concentrations of thyroid stimulating hormone (geometric mean) at the end of the first period of treatment were 2.0 mU/l and 1.9 mU/l in groups 1 and 2, respectively. In the interval without treatment hypothyroidism recurred and the mean concentration of thyroid stimulating hormone, 32 mU/l and 27 mU/l in groups 1 and 2 respectively, reached the concentration observed before the study (NS by paired *t* test in both groups).

Methimazole was detected in all serum samples obtained from patients in group 1, 22 weeks after the start of treatment with that drug. The mean (SEM) concentration of methimazole was 88 (9) ng/ml. Seven of the patients in group 1 agreed to repeated fine needle aspiration thyroid biopsy in the interval without treatment, and lymphocytic thyroiditis was still present in all.

Discussion

In this study we found that hypothyroid patients with Hashimoto's thyroiditis treated with thyroxine to attain the euthyroid state showed decreased serum thyroid microsomal autoantibody titres. Addition of methimazole (30 mg daily) had

Mean (SD) pretreatment data on patients with Hashimoto's thyroiditis. No significant differences were observed between the two groups

Variable	Patients receiving combined thyroxine and methimazole (n = 10)	Patients receiving thyroxine alone (n = 10)
Age, in years	44 (17)	48 (10)
Free thyroxine index*	55 (18)	63 (23)
Free triiodothyronine index†	1.4 (0.5)	1.5 (0.4)
Thyroid stimulating hormone (mU/l)‡	32 (13-81)§	22 (10-48)§

Reference ranges: *67-153; †1.2-2.8; ‡≤8 mU/l.
§Geometric mean (SD).

no further effect on the titre changes. This last finding contradicts a previous report on patients with Hashimoto's thyroiditis,⁹ who were treated for 12 weeks with 45 mg carbimazole (which through bioactivation, is converted to 27.5 mg methimazole.¹⁰) Carbimazole was introduced when the patients were already receiving thyroxine, and it was reported to have the effect of lowering thyroid microsomal autoantibody titres. Although the designs of these studies were not identical, no obvious explanation exists for this discrepancy.

The view that antithyroid drugs are immunosuppressive *in vivo* is controversial.¹¹ Immunosuppressive effects of methimazole *in vitro* on lymphocytes^{4, 12} and monocytes^{7, 8} have generally been observed at drug concentrations higher than those measured in the thyroid.⁶ Furthermore, it has been shown that methimazole is not accumulated in lymphocytes from patients with Graves' disease.¹³ Moreover, in two studies methimazole was found to enhance lymphocyte proliferative responses to lectins, whereas propylthiouracil had a suppressive action.^{14, 15} Thus alternative explanations may be sought to explain the antibody reducing effect of thyrostatic treatment in Graves' thyrotoxicosis and the similar effect observed in the present study. Possibly, thyroxine in hypothyroid patients with Hashimoto's thyroiditis, with consequent reduction in stimulatory thyroid stimulating hormone concentrations, alters the characteristics of the thyrocytes so that the "autoimmune signal" decreases. This would occur if, for instance, the amount of thyroid autoantigens were decreased or, alternatively, if HLA-DR antigenicity were reduced. Expression of HLA-DR antigens on thyroid cells in diseased but not in normal states was reported recently.^{16, 17}

Our data thus suggest that, in the management of patients with autoimmune disorders, immunosuppressive effects might be achieved not only by classic drugs acting directly on the immunocompetent cells but also by drugs altering the target cells within the diseased organ so that their autoimmune stimulus is reduced.

This work was supported by grants from Tore Nilson Foundation, Nordic Insulin Foundation, and the Swedish Medical Research Council (No 4996).

References

- Pinchera A, Liberti P, Martino E, *et al.* Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. *J Clin Endocrinol Metab* 1969;29:231-8.
- Fenzi GF, Hashizume K, Roubeshou CP, De Groot LJ. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. *J Clin Endocrinol Metab* 1979;48:572-6.
- Teng CS, Yeung RTT. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. *J Clin Endocrinol Metab* 1980;50:144-7.
- McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith RB, Hall R. Carbimazole and the autoimmune response in Graves' disease. *N Engl J Med* 1980;303:302-7.
- Karlsson PA, Dahlberg PA. Thyroid stimulating antibodies (TSAb) in patients with Graves' disease undergoing antithyroid drug treatment—indicators of activity of disease. *Clin Endocrinol* 1981;14:579-85.
- Jansson R, Dahlberg PA, Johansson H, Lindström B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. *J Clin Endocrinol Metab* 1983;57:129-32.
- Weetman AP, McGregor AM, Hall R. Methimazole inhibits thyroid autoantibody production by an action on accessory cells. *Clin Immunol Immunopathol* 1983;28:39-45.
- Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. *Br Med J* 1984;288:518-20.
- McGregor AM, Ibbertson HK, Smith BR, Hall R. Carbimazole and autoantibody synthesis in Hashimoto's thyroiditis. *Br Med J* 1980;281:968-9.
- Jansson R, Dahlberg PA, Lindström B. Comparative bioavailability of carbimazole and methimazole. *Int J Clin Pharmacol Ther Toxicol* 1983;21:505-10.
- Kendall-Taylor P. Are antithyroid drugs immunosuppressive? *Br Med J* 1984;288:509-11.
- Weiss I, Davies TF. Inhibition of immunoglobulin-secreting cells by antithyroid drugs. *J Clin Endocrinol Metab* 1981;53:1223-8.
- Shewring GS, Lazarus JH. The accumulation of ¹²⁵I-methimazole by human and rat lymphocytes. *Acta Endocrinol (Copenh)* 1983;102:68-70.
- Hallengren B, Forsgren A, Melander A. Effects of antithyroid drugs on lymphocyte function *in vitro*. *J Clin Endocrinol Metab* 1980;51:298-301.
- Okabe N, Inoue K, Mori R. Effects of antithyroid drugs on lymphocyte proliferative responses to lectins: relationship between insulin autoimmune syndrome and methimazole. *J Clin Lab Immunol* 1983;11:167-71.
- Hanafusa T, Pujol-Borrell R, Chiovato L, Russel RCG, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity. *Lancet* 1983;ii:1111-5.
- Jansson R, Karlsson A, Forssum U. Intrathyroidal HLA-DR expression and T lymphocyte phenotypes in Graves' thyrotoxicosis, Hashimoto's thyroiditis and nodular colloid goitre. *Clin Exp Immunol* (in press).

(Accepted 8 October 1984)